Atossa Therapeutics, Inc.

NASDAQ:ATOS

0.96 (USD) • At close January 6, 2025
Bedrijfsnaam Atossa Therapeutics, Inc.
Symbool ATOS
Munteenheid USD
Prijs 0.96
Beurswaarde 120,806,700
Dividendpercentage 0%
52-weken bereik 0.77 - 2.31
Industrie Biotechnology
Sector Healthcare
CEO Dr. Steven C. Quay FCAP, M.D., Ph.D.
Website https://www.atossatherapeutics.com

An error occurred while fetching data.

Over Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also

Vergelijkbare Aandelen

INmune Bio, Inc. logo

INmune Bio, Inc.

INMB

5.41 USD

FONAR Corporation logo

FONAR Corporation

FONR

15.34 USD

Societal CDMO, Inc. logo

Societal CDMO, Inc.

SCTL

1.1 USD

Omega Therapeutics, Inc. logo

Omega Therapeutics, Inc.

OMGA

0.884 USD

Greenwich LifeSciences, Inc. logo

Greenwich LifeSciences, Inc.

GLSI

13.11 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)